, a Spanish healthtech startup specialising in the use of imaging biomarkers for precision medicine, has snapped $50 million in Series A financing. The round was co-led by Asabys (through Sabadell Asabys II) and Buenavista Equity Partners (via BHG I fund), alongside new investors UI Investissements and GoHub Ventures. Existing investors, including Amadeus Capital Partners (which recently invested in iPronics and Inotec), APEX Ventures, Partech, Adara Ventures, Leadwind, Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, also participated.
Expansion plans on cards
The investment will be used for the following:
- Drive product expansion: Enhance foundational AI models for analysing whole-body scans, supporting global healthcare needs.
- Strengthen US presence: Build on Quibim’s European success with strategic collaborations in the U.S. healthcare and pharmaceutical sectors.
- Fuel growth: Scale operations to support growing demand.
What challenges does it address?
As imaging datasets grow exponentially, healthcare faces mounting complexity in managing and analysing scans. Quibim tackles this challenge with foundational AI models that extract actionable insights from MRI, CT, and PET scans. These models offer precise disease characterisation and predict outcomes in oncology, immunology, neurology, and metabolic disorders. The company’s innovative solutions are set to revolutionise diagnostics, drug development, and patient care.
AI-powered imaging biomarkers
Founded in 2015 by Dr. Angel Alberich-Bayarri and Dr. Luis Marti-Bonmati, Quibim is on a mission to unlock a comprehensive, non-invasive understanding of human health. The company’s technology bridges the gap between research, clinical practice, and drug development by leveraging AI-powered imaging biomarkers.
Its vision is to create human digital twins, dynamic models of patients’ health that enable personalised monitoring, treatment testing, and enhanced drug development. Their advanced solutions include QP-Prostate, QP-Brain, QP-Liver, and QP-Insights, which together analyse medical imaging data at an unprecedented scale.
With over 170 installations worldwide, the company has entered into partnerships with Mass General Brigham and Stanford. Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.
“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr. Ángel Alberich Bayarri, CEO and co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionise diagnostics and improve patient outcomes.”
What lies ahead for Quibim?
With regulatory clearances across the US, EU, and UK, Quibim is set to redefine healthcare through precision diagnostics, improved clinical trial outcomes, and accelerated drug development. By harnessing imaging biomarkers, it positions itself as a leader in precision medicine, poised to impact millions of lives worldwide.
“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space,” said Guillem Masferrer, Partner at Asabys Partners. “Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”
“Quibim’s technology exemplifies the next wave of precision medicine,” said José Mesa, Partner at Columbus and Buenavista’s representative on the Board. “Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”
“The foundational research done by Quibim’s team has not only informed industry standards but also led to the company pioneering an approach to combining radiomics and deep learning that is now a standard of its own,” said Pierre Socha, Partner at Amadeus Capital Partners. “This platform approach was novel at the time of our first investment and proved to be the right strategy for rapid scale-up.”
“Excited that Quibim’s AI-enabled insights from MRI, CT and PET scans are coming to the US! Their FDA-approved precision analysis is already being used by doctors to detect early signs of diseases like cancer and help measure treatment response. Quibim has truly advanced precision medicine around the world!” said Tony Fadell Build Collective Principal and Nest Founder.
